The PennZone

  • Home
  • Non-profit
  • Books
  • Entertainment
  • Music
  • Marketing
  • Health
  • Legal
  • Artificial Intelligence

Olympus Acquires Veran Medical Technologies, Inc.
The PennZone/10102444

Trending...
  • Growth Story Expands: $54.6M Contract, $30M Revenue Run Rate, 800+ Customers, 50+ Patents & New AI Cybersecurity Products for Cycurion, Inc $CYCU
  • Nutriband Inc. (N A S D A Q: NTRB) Breaks Into Uncharted Territory: 52-Week High Eclipsed as Shares Surge 22% —AVERSA™ Puts Investors on High Alert
  • Dr. Jay Johannigman Returns to Cincinnati Following 46 Years of Military Service
CENTER VALLEY, Pa. and TOKYO, Dec. 30, 2020 /PRNewswire/ -- Olympus Corporation today announced that it has finalized the acquisition of Veran Medical Technologies, Inc. (VMT), a leading provider of advanced medical devices specializing in interventional pulmonology, following the definitive agreement the two companies signed December 4, 2020. With this acquisition by Olympus subsidiary Olympus Corporation of the Americas (OCA), Olympus gains VMT's global sales network, marketing, manufacturing, R&D, and other functions to expand the Olympus respiratory product portfolio.

Lung cancer is the leading cause of cancer-related deaths globally.1 With increased awareness and more lung cancer screenings using low-dose computed tomography (CT), the need for definitive diagnosis of lesions in the peripheral regions of the lungs by tissue biopsy is expected to increase. VMT's SPiN Thoracic Navigation System® and related devices are specifically designed to help physicians navigate to, localize, and sample peripheral pulmonary lesions. Together with the existing Olympus respiratory portfolio that includes radial endobronchial ultrasound (EBUS) and thin bronchoscopes, VMT's navigational system and related devices provide a powerful combination of imaging, access and precision for pulmonologists seeking to diagnose and determine the stage of a patient's lung cancer.

More on The PennZone
  • NYC Banners Delivers High-Stakes UN General Assembly Backdrop for the US Department of State Event
  • OneVizion Appoints Energy Infrastructure Executive Walt Farrell to Board of Directors
  • Tampa Bay Reporter Launches with a Mission to Deliver Local News with National Reach
  • "JACKIE the STRIPPER," Starring Charlotte Kirk and The PUSSYCAT DOLLS' Kimberly Wyatt, Now Streaming on PRIME
  • Migguel Anggelo Celebrates the Immigrant Experience, Latino Identity, and the Power of Iconic Latin Rhythms During Hispanic Heritage Month

"We are very excited about the synergies this acquisition creates. With the deal now closed, as one company we are able to combine Olympus' expertise and clinical history in minimally invasive technology with the innovation in navigation systems of Veran Medical Technology to improve workflow and patient care in lung cancer," said Lynn Ray, Vice President and General Manager of the Global Respiratory Business Unit for Olympus Corporation. "Olympus is committed to providing the medical community with the best tools possible to use in their fight against cancer. With the advent of EBUS-guided transbronchial needle aspiration (EBUS-TBNA) in 2004, Olympus brought patients the benefit of more accurate diagnosis and staging, to improve patient outcomes and care. We are thrilled to be at the forefront of development in this rapidly evolving area of respiratory care."

The acquisition will provide immediate incremental revenue and an experienced sales team within the U.S. market. VMT's advanced and proven navigation technology, together with Olympus' respiratory portfolio, strengthens and enhances Olympus' global position as a medical technology innovator.

As part of its current Corporate Strategy, Olympus vowed to "focus and scale" its Therapeutic solutions Division (TSD). To accelerate the process and provide greater agility, Olympus made OCA the TSD headquarters, recognizing the significant growth opportunities in North America. Olympus also identified three core medical fields to prioritize and has since focused on gastroenterological endotherapy devices, urological devices, and respiratory devices. The VMT acquisition is centered on respiratory devices and will position Olympus as a leader in this field.

More on The PennZone
  • Indianapolis Criminal Defense Firm Rigney Law LLC Relaunches Criminal Law Podcast "Tales from the Brown Desk"
  • 3ptechies Makes Its Articles Audio-Ready With Instaread Voice Technology
  • Genuine Hospitality, LLC Selected to Operate Fairfield Inn & Suites Tampa Wesley Chapel
  • Pregis to Highlight EPR Expertise, Sustainable Packaging Solutions and Live Automation Demonstrations at Pack Expo International 2026
  • Infinity Infusion Solutions Launches "Women Leading Infusion Care" Campaign for National Women in Business Month

For additional information, please refer to our corporate disclosure, "Notice regarding acquisition of Veran Medical Technologies, Inc. in the United States."

(available at: https://www.olympus-global.com/news/ir/2020/)

1 WHO data:  https://www.who.int/news-room/fact-sheets/detail/cancer

About Olympus' Therapeutic Solutions Division
In its Therapeutic Solutions business, Olympus uses innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic, and minimally invasive procedures to improve clinical outcomes, reduce overall costs, and enhance the quality of life for patients. Starting with its early contributions to the development of the polypectomy snare, Olympus' Therapeutic Solutions portfolio has grown to include an array of surgical energy devices and a wide range of instruments to help prevent, detect, and treat disease. For more information, visit www.olympus-global.com.

SOURCE Olympus

Related Links

http://www.olympus.com/
Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Curtis Salgado shares a love letter to the city of Chicago and Otis Rush with new single
  • Oral statement on the situation of Chairman Lee Man-hee in pretrial detention in the Republic of Korea
  • Names Are Not Important Asks What Remains When Identity Is Stripped of Labels
  • UVIFY Brings Advanced Autonomous Systems Research to IROS 2026 in Pittsburgh
  • Mad Darbarian is available for views as a Horror Host
  • Most Utah Deaths Never Reach the Medical Examiner. Postmortem Pathology Offers Salt Lake City a Private Autopsy Option
  • Virtually Tour Heritage at South Brunswick's Resort-Style Living - Experience Indoor and Outdoor Amenities at Your Fingertips
  • Derek Cook's Roofing Encourages Homeowners to Prepare for Fall Weather
  • Boston Industrial Solutions Expands Product Offering with Pad Printing Pads and Silicone for Custom Pad Manufacturing
  • Rodeo FX Originals Appoints Yvann Thibaudeau Head of Development & IP
  • Phoenix 5/7 Emerges as a Genre-Fluid Artist Collective
  • Massage Revolution Expands to Santa Monica With New Wilshire Boulevard Location
  • "Warrior Defined" Event Brings Men Together in Charlotte, With Calls for Events Across the U.S
  • Dion Abadi Publishes Free Collector Tips Hub for Art and Jewelry Buyers
  • World-Renowned Body Language Expert Mark Bowden Headlines INSPIRE Northwest 2026 in Wenatchee, WA
  • ASN Software Introduces New California CARS Act Dealer Updates
  • USA Air Management Marks 30 Years of Air Duct Cleaning in NJ Urges Homeowners to Schedule Dryer Vent Cleaning Before Heating Season
  • Dr. Jay Johannigman Returns to Cincinnati Following 46 Years of Military Service
  • Mud Morganfield Bares His Soul on 7" Single, 'Deep Gospel'
  • Allstream Energy Partners, SEO Experts in Oil and Gas, Awarded Gas Processing OEM Agreement

Popular on PennZone

  • Benny Turner Revisits Freddie King's Legacy for 50th Anniversary of His Passing - 247
  • Church Tradition Takes an Unexpected Turn at the Ford Community & Performing Arts Center - 213
  • GitKraken Names Jim Shaw CEO as Software Teams Move From AI Adoption to Multi-Agent Orchestration - 169
  • Brévant Guide Launches New National Restaurant Guide Across Canada - 137
  • VC Fast Pitch and Steamwork Ventures Bring Startup & Investor Networking Event to Santa Barbara on October 8 - 122
  • FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
  • SHI Introduces the RP-222B3S, Its Highest-Capacity 4K Pulse Tube Cryocooler
  • Sea Tales Strengthens U.S. Leadership Team as Retail Expansion Accelerates
  • Robert DeMaio, Phinge CEO to Speak at 30th IIPLA 2026 on Securing IP, User Data & Digital Sovereignty via Verified App-less Tech. Attend the Live Q&A!
  • Mandeville Pests May Pose Serious Health Risks for Your Family

Similar on PennZone

  • NIL Club Data Shows Brands Are Looking Beyond Follower Counts in College Sports
  • NYC Banners Delivers High-Stakes UN General Assembly Backdrop for the US Department of State Event
  • Genuine Hospitality, LLC Selected to Operate Fairfield Inn & Suites Tampa Wesley Chapel
  • Pregis to Highlight EPR Expertise, Sustainable Packaging Solutions and Live Automation Demonstrations at Pack Expo International 2026
  • Infinity Infusion Solutions Launches "Women Leading Infusion Care" Campaign for National Women in Business Month
  • HuskyTail Digital Puts AI to Work Behind the Scenes to Cut Client Turnaround Time
  • AI, Real-World Data "RWD" and U.S. Expansion Put Predictive Healthcare in Focus for POMDOCTOR Ltd. (N A S D A Q: POM)
  • $11.18 Million DARPA Award Ignites a Major New Catalyst as FDA, Robotic TMS and Commercialization Milestones Converge for NRx Pharmaceuticals, Inc
  • Nutriband (N A S D A Q: NTRB): Fighting Back Against the Fentanyl Crisis With a New Approach to Safer Transdermal Medicines
  • Most Utah Deaths Never Reach the Medical Examiner. Postmortem Pathology Offers Salt Lake City a Private Autopsy Option
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us